Novartis' top drugs based on revenue 2023
Cardiovascular drug Entresto was Novartis’ best-selling pharmaceutical during 2023, with a total revenue of around six billion U.S. dollars worldwide. Novartis is one of the big pharma companies with the lowest share of its top three products related to total sales. This broadly-based revenue makes it less vulnerable to revenue losses through patent expirations.
A view on the company
Novartis is based in Basel, Switzerland, and is among the world’s largest pharmaceutical company based on prescription drug sales. Interestingly, another leading drug manufacturer – Roche – is based also in Basel, making it the only city to be home to two global top 10 pharma companies. Both companies are deeply involved in the research, development, and manufacturing of cancer treatments. Both companies generate a large part of their pharmaceutical revenues through oncologic products.
Development of segments and divisions
Through its subsidiary Alcon, Novartis was also the second largest company worldwide in the field of ophthalmology products. However, in April 2019, Alcon’s spin-off from Novartis was completed, making it a wholly independent company. With Sandoz, Novartis had also a strong generic drug division, until it was spun-off in mid-2023. Until 2014-2015, Novartis also had three other divisions which have since been sold: consumer health products, vaccines and diagnostics, and animal health. Thus, the company’s development shows a clear focus on human medicine and innovative pharmaceuticals.
A view on the company
Novartis is based in Basel, Switzerland, and is among the world’s largest pharmaceutical company based on prescription drug sales. Interestingly, another leading drug manufacturer – Roche – is based also in Basel, making it the only city to be home to two global top 10 pharma companies. Both companies are deeply involved in the research, development, and manufacturing of cancer treatments. Both companies generate a large part of their pharmaceutical revenues through oncologic products.
Development of segments and divisions
Through its subsidiary Alcon, Novartis was also the second largest company worldwide in the field of ophthalmology products. However, in April 2019, Alcon’s spin-off from Novartis was completed, making it a wholly independent company. With Sandoz, Novartis had also a strong generic drug division, until it was spun-off in mid-2023. Until 2014-2015, Novartis also had three other divisions which have since been sold: consumer health products, vaccines and diagnostics, and animal health. Thus, the company’s development shows a clear focus on human medicine and innovative pharmaceuticals.
